Currently, isocitrate dehydrogenase (IDH) and O6-methylguanine-DNA methyltransferase (MGMT) are the most common molecular biomarkers associated with glioma progression and prognosis (Molenaar et al., 2014; Valiyaveettil et al., 2018). This evidence concerns the gene MGMT and central nervous system cancer.